Myelofibrosis (MF) is an uncommon type of bone marrow cancer that disrupts the body’s normal production of blood cells. It causes extensive scarring to bone marrow leading to severe complications. There is a significant unmet need for improved therapies in patients with MF who have had a relapse with the treatments available. Most patients are intolerant to the current medications.
Revive Research Institute is investigating a new investigational drug therapy to maximize responsiveness and discover a novel and effective treatment for myelofibrosis. The investigational drug aims to decrease inflammation while not affecting the cells involved with natural defenses.
- Adults 18 years of age or older, male or female
- Confirmed diagnosis of PMF, post-PV MF, or post-ET MF
- Must have one of the following:
- Relapsed or refractory MF following JAKi treatment
- JAKi intolerant MF
- JAKi treatment ineligible MF
- Additional criteria may apply
Our group of licensed and certified physicians will be keeping track of the patient’s progress throughout the study and will address any concerns or queries that arise regarding the research trial. The investigational treatment is free for the duration of the clinical trial and insurance is not required.The patient will also receive compensation for their time and involvement.